Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trialAlvin F. Wells, Jacob Aelion, Christopher J Edwards et al.|Lara D. Veeken|2018Cited by 101
Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysisArthur Kavanaugh, Philip J. Mease, Dafna D. Gladman et al.|Arthritis Research & Therapy|2019Cited by 80
Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trialLoretta Fiorillo, Lisa M. Arkin, Emily Becker et al.|Journal of the American Academy of Dermatology|2024Cited by 28
Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled TrialsPhilip J. Mease, J. Wollenhaupt, Éric Lespessailles et al.|ACR Open Rheumatology|2020Cited by 21
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patientsAlvin F. Wells, Jacob Aelion, Christopher J Edwards et al.|Lara D. Veeken|2021Cited by 12